BioPharma Solutions, previously owned by Baxter International Inc., was sold to Advent International and Warbug Pincus in May. As part of the $4.25 billion deal, Baxter’s BioPharma Solutions will be renamed Simtra BioPharma Solutions.
Read more: Baxter selling off BioPharma wing to equity investment firms
It will now be a fully independent contract development and manufacturing organization (CDMO), but will continue to ensure supply of pharmaceutical products to customers.
Simtra said it will focus on community-based growth, as the Bloomington facility plans to bring new job opportunities to the region.
By partnering with pharmaceutical and biotech companies, the business will specialize in sterile injectables to provide scientific help. The goal is to solve injectable medicine production issues, according to an email from Simtra to WFIU/WTIU News.
Simtra has about 1,700 employees who will continue working at manufacturing sites in Bloomington and Germany, as well as at corporate headquarters, which is under development in New Jersey.
The Bloomington facility has been in operation for 27 years under the Baxter name, and is now one of the largest contract manufacturers of sterile products in North America.